Health In Tech Q2 2026 Earnings: Lower Revenue and Higher Costs Drive a Loss

Health In Tech (Nasdaq: HIT) reported Q2 2026 revenue of $8.1 million, down 13.5% from $9.3 million a year earlier, while diluted EPS fell to $(0.04) from $0.01. Gross margin contracted sharply as cost of revenue increased despite lower sales, and operating cash flow swung to a $2.9 million outflow. The company nevertheless reaffirmed its full-year revenue guidance, supported by contracted business and a larger but partly uncommitted pipeline.

Core Earnings Data

Both of HIT’s revenue streams declined during the quarter. At the same time, cost of revenue increased 37.6% to $4.1 million, causing gross profit to fall much faster than revenue.

Operating expenses rose 31.8% to $7.4 million. Sales and marketing spending increased about 80.6%, research and development rose about 50.3%, and general and administrative expenses increased about 13.1%, reflecting the company’s continued investment in distribution, technology, and product development.

Adjusted EBITDA is a non-GAAP measure. A $0.8 million income tax benefit partly cushioned the quarter’s $3.3 million pre-tax loss.

Business and Operating Metrics

SMR fee revenue remained HIT’s largest revenue source but declined moderately. ICE underwriting-modeling revenue recorded a much steeper contraction and accounted for most of the company’s overall revenue decline.

Distribution partners reached 933 at June 30, an increase of 19.9% year over year. However, that network expansion had not yet translated into higher quarterly GAAP revenue.

Platform Placed Plan Value was $84.0 million at quarter-end. This figure measures the full contractual value of plans placed through HIT’s platform—including premiums, claim funding, and administrative fees—and is not the company’s revenue or take rate.

Forward Revenue Metrics Have Yet to Convert Into Reported Growth

HIT reported first-half Contracted Revenue of $32.3 million, representing expected revenue over the full terms of policies already secured. The company said $14.0 million was expected to be recognized in the second half of 2026 and another $1.0 million in 2027.

The release also states that $17.3 million of Contracted Revenue had been recognized in the first half, while the income statement reports $16.8 million of total first-half revenue. No reconciliation for that difference was provided.

As of July 31, Pipeline Revenue stood at $66.3 million. Of that amount, $1.9 million had been contracted after quarter-end, while $64.4 million remained in quoting or binding status. HIT estimates a conversion rate of 15% to 40%, meaning a substantial portion is not yet contractually secured and may not become revenue.

Based on that range, management estimated the uncontracted pipeline could generate $9.7 million to $25.8 million of additional Contracted Revenue. The company expects $3.1 million to $8.3 million of the resulting GAAP revenue to be recognized in 2026, with the remainder spread into 2027.

Cash Flow and Balance Sheet

Operating cash flow was negative $2.9 million in Q2, compared with positive $1.5 million a year earlier. A $4.8 million quarterly increase in accounts receivable was the largest working-capital use, partly offset by a $2.9 million increase in accounts payable and accrued expenses.

For the first six months of 2026, operating cash outflow reached $6.2 million, versus a $2.0 million inflow in the prior-year period. HIT also spent $1.0 million on software development. A $6.0 million financing inflow, which included $6.4 million of net PIPE proceeds, partly offset these uses of cash.

Cash and cash equivalents ended the quarter at $6.5 million, down from $7.7 million at December 31, 2025. Accounts receivable increased to $8.5 million from $0.8 million over the same period, while accounts payable and accrued expenses rose to $9.9 million from $4.2 million. The growth in receivables makes collection timing an important factor for future cash flow.

Revenue Guidance

Health In Tech reaffirmed its full-year 2026 revenue guidance of $45 million to $50 million. With first-half revenue of $16.8 million, the company would need approximately $28.2 million to $33.2 million of second-half revenue to reach that range, making contract conversion and recognition timing central to execution.

The $14.0 million of Contracted Revenue scheduled for second-half recognition provides some visibility, but the guidance also depends on additional business becoming eligible for GAAP recognition.

Management Commentary

CEO Tim Johnson attributed higher spending to investments in sales, marketing, technology, product development, and key personnel, supported in part by the PIPE financing. Management expects these investments to expand the distribution network and improve product execution, although they weighed on current profitability.

The company contractually secured its first employer group for its Three-Year Rate Stabilization Program. HIT also remains on track to launch HitRix, its next-generation marketplace platform, in the second half of 2026. The platform is intended to automate document extraction, plan comparisons, and competitive bidding across brokers, carriers, administrators, and employer groups.

Recent Insider Transactions

The latest ten reported insider transactions in the supplied data were stock awards or grants rather than open-market purchases or sales. The separate six-month summary showed zero insider purchases and zero sales, with total insider holdings of 40.6 million shares.

These grants do not by themselves indicate insiders’ views on the company’s valuation or outlook.

Risks Investors Need to Watch

• Margin pressure: Cost of revenue increased while sales declined, reducing gross margin by about 19.1 percentage points. Continued pressure would make a return to profitability more difficult.
• Pipeline conversion: Most of the $66.3 million pipeline was still in quoting or binding status. The company’s 15% to 40% conversion assumption covers a wide range, and some opportunities may not convert.
• Guidance execution: Reaching the reaffirmed full-year range requires second-half revenue to be materially higher than first-half revenue, increasing the importance of contract timing and new business.
• Cash conversion: Operating cash burn and the sharp increase in accounts receivable could pressure liquidity if collections do not keep pace with expenses.
• Product and program execution: HitRix and the Three-Year Rate Stabilization Program are intended to support future growth, but the financial contribution and timing of these initiatives have not been quantified.

Conclusion

Health In Tech’s Q2 2026 results showed a difficult combination of lower revenue, sharply reduced gross margin, higher operating spending, and negative cash flow. Distribution and forward-looking contract metrics expanded, but converting those indicators into recognized revenue and cash will be critical to meeting the reaffirmed 2026 guidance while limiting further balance-sheet pressure.